Role of Fibroblast Growth Factor-23 in Peripheral Vascular Calcification in Non-diabetic and Diabetic Hemodialysis Patients

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2006 Aug 10

PMID 16896512

Citations 42

Authors

M Inaba

S Okuno

Y Imanishi

S Yamada

A Shioi

T Yamakawa

E Ishimura

Y Nishizawa

Affiliations

Soon will be listed here.

Abstract

Introduction: Fibroblast growth factor (FGF) 23 is a recently identified circulating factor that regulates phosphate (Pi) metabolism. Since the derangement of Pi control is an important risk factor for vascular calcification, we investigated the importance of plasma FGF-23 in the development of vascular calcification in the aorta and peripheral artery in hemodialysis patients with and without diabetes mellitus (DM).

Methods: Male hemodialysis patients with DM (n=32) and without DM (n=56) were examined. Plasma samples were obtained before the start of dialysis sessions, and the FGF-23 levels were determined by enzyme-linked immunosorbent assay. Roentgenography of the aorta and hand artery was performed, and visible vascular calcification was evaluated by one examiner, who was blinded to the patient characteristics.

Results: In the 56 non-DM hemodialysis patients, vascular calcification was found in the hand artery in 5 patients (8.9%) and in the aorta in 23 patients (41.1%). These levels were significantly lower (p<0.05) than in the 32 DM patients, of whom, 19 (59.4%) and 21 (65.6%) had vascular calcification of the hand artery and aorta, respectively. Multiple regression analyses performed separately in the non-DM and DM patients showed that the plasma FGF-23 level, CaxPi product, and body weight are independent factors significantly associated with hand-artery calcification and that diastolic blood pressure is associated with aorta calcification in non-DM patients. In DM patients, the plasma FGF-23 level and hemodialysis duration emerged as independent factors associated with hand-artery calcification and diastolic blood pressure was associated with aorta calcification. The independent association of the plasma FGF-23 level with hand-artery calcification was retained in both non-DM and DM patients when adjusted for the CaxPi product.

Conclusion: Our findings show that the plasma FGF-23 level is an independent factor negatively associated with peripheral vascular calcification in the hand artery, but not in the aorta, in both male non-DM and DM hemodialysis patients, even when adjusted for the CaxPi product. This study raises the possibility that the plasma FGF-23 level may provide a reliable marker for Moenckeberg's medial calcification in male hemodialysis patients, independent of its regulatory effect on Pi metabolism.

Citing Articles

Fibroblast Growth Factor-23 in Pre-Dialysis Chronic Kidney Disease Patients and its Correlation with Carotid Artery Calcification.

Kumar T, Mohanty S, Rani A, Malik A, Kumar R, Bhashker G Indian J Nephrol. 2023; 32(6):560-566.

PMID: 36704592 PMC: 9872934. DOI: 10.4103/ijn.IJN_506_20.

FGF23 and Cardiovascular Structure and Function in Advanced Chronic Kidney Disease.

Halim A, Burney H, Li X, Li Y, Tomkins C, Siedlecki A Kidney360. 2022; 3(9):1529-1541.

PMID: 36245643 PMC: 9528374. DOI: 10.34067/KID.0002192022.

Arrhythmias in Chronic Kidney Disease.

Akhtar Z, Leung L, Kontogiannis C, Chung I, Bin Waleed K, Gallagher M Eur Cardiol. 2022; 17:e05.

PMID: 35321526 PMC: 8924956. DOI: 10.15420/ecr.2021.52.

Fibroblast Growth Factor 23 as Regulator of Vitamin D Metabolism.

Nakatani S, Nakatani A, Mori K, Emoto M, Inaba M, Razzaque M Adv Exp Med Biol. 2022; 1362:47-54.

PMID: 35288872 DOI: 10.1007/978-3-030-91623-7_6.

Paradoxical positive association of serum adiponectin with all-cause mortality based on body composition in Japanese haemodialysis patients.

Machiba Y, Inaba M, Mori K, Kurajoh M, Nishide K, Norimine K Sci Rep. 2018; 8(1):14699.

PMID: 30279489 PMC: 6168594. DOI: 10.1038/s41598-018-33011-y.

References

Econs M, McEnery P . Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab. 1997; 82(2):674-81. DOI: 10.1210/jcem.82.2.3765. View

Ishimura E, Okuno S, Kitatani K, Maekawa K, Izumotani T, Yamakawa T . C-reactive protein is a significant predictor of vascular calcification of both aorta and hand arteries. Semin Nephrol. 2004; 24(5):408-12. DOI: 10.1016/j.semnephrol.2004.06.008. View

Inaba M, Nakatsuka K, Imanishi Y, Watanabe M, Mamiya Y, Ishimura E . Technical and clinical characterization of the Bio-PTH (1-84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone. Clin Chem. 2003; 50(2):385-90. DOI: 10.1373/clinchem.2003.026831. View

Gupta A, Winer K, Econs M, Marx S, Collins M . FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab. 2004; 89(9):4489-92. DOI: 10.1210/jc.2004-0724. View

Inaba M, Okuno S, Imanishi Y, Ueda M, Yamakawa T, Ishimura E . Significance of Bio-intact PTH(1-84) assay in hemodialysis patients. Osteoporos Int. 2004; 16(5):517-25. DOI: 10.1007/s00198-004-1715-1. View

Mirams M, Robinson B, Mason R, Nelson A . Bone as a source of FGF23: regulation by phosphate?. Bone. 2004; 35(5):1192-9. DOI: 10.1016/j.bone.2004.06.014. View

Lehto S, Niskanen L, Suhonen M, Ronnemaa T, Laakso M . Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1996; 16(8):978-83. DOI: 10.1161/01.atv.16.8.978. View

Imel E, Econs M . Fibroblast growth factor 23: roles in health and disease. J Am Soc Nephrol. 2005; 16(9):2565-75. DOI: 10.1681/ASN.2005050573. View

Ishimura E, Okuno S, Kitatani K, Kim M, Shoji T, Nakatani T . Different risk factors for peripheral vascular calcification between diabetic and non-diabetic haemodialysis patients--importance of glycaemic control. Diabetologia. 2002; 45(10):1446-8. DOI: 10.1007/s00125-002-0920-8. View

10.

Cozzolino M, Dusso A, Slatopolsky E . Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. J Am Soc Nephrol. 2001; 12(11):2511-2516. DOI: 10.1681/ASN.V12112511. View

11.

Gomez Jr B, Ardakani S, Ju J, Jenkins D, Cerelli M, Daniloff G . Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem. 1995; 41(11):1560-6. View

12.

Wanner C, Zimmermann J, Schwedler S, Metzger T . Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl. 2002; (80):99-102. DOI: 10.1046/j.1523-1755.61.s80.18.x. View

13.

Nishizawa Y, Jono S, Ishimura E, Shioi A . Hyperphosphatemia and vascular calcification in end-stage renal disease. J Ren Nutr. 2005; 15(1):178-82. DOI: 10.1053/j.jrn.2004.09.027. View

14.

Yamashita T, Yoshioka M, Itoh N . Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 2000; 277(2):494-8. DOI: 10.1006/bbrc.2000.3696. View

15.

Sezer S, Ozdemir F, Arat Z, Turan M, Haberal M . Triad of malnutrition, inflammation, and atherosclerosis in hemodialysis patients. Nephron. 2002; 91(3):456-62. DOI: 10.1159/000064287. View

16.

Miwa Y, Tsushima M, Arima H, Kawano Y, Sasaguri T . Pulse pressure is an independent predictor for the progression of aortic wall calcification in patients with controlled hyperlipidemia. Hypertension. 2004; 43(3):536-40. DOI: 10.1161/01.HYP.0000117153.48029.d1. View

17.

Arici M, Walls J . End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link?. Kidney Int. 2001; 59(2):407-14. DOI: 10.1046/j.1523-1755.2001.059002407.x. View

18.

Kimura K, Saika Y, Otani H, Fujii R, Mune M, Yukawa S . Factors associated with calcification of the abdominal aorta in hemodialysis patients. Kidney Int Suppl. 1999; 71:S238-41. DOI: 10.1046/j.1523-1755.1999.07163.x. View

19.

Benet-Pages A, Orlik P, Strom T, Lorenz-Depiereux B . An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet. 2004; 14(3):385-90. DOI: 10.1093/hmg/ddi034. View

20.

Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T . Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004; 113(4):561-8. PMC: 338262. DOI: 10.1172/JCI19081. View